Company intelligence / Profile preview

Simmunome

Montreal, Quebec, Canada

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Simmunome has developed a validated AI-driven simulation platform that models disease biology to predict drug target efficacy and safety. The technology has demonstrated high accuracy in predicting clinical trial outcomes retrospectively and is used by pharma clients to de-risk R&D decisions. The company has signed its first client in regenerative medicine and expanded into multiple therapeutic areas. No direct clinical results since it does not run trials itself.

Therapeutic areas: OncologyNeurologyOther
Modalities: Computational disease modelingMechanistic modelingMachine learning simulations
Industry: Drug Discovery Services

Partnerships

Quebec universities including McGill University/The Neuro at McGill, Université Laval, Université de Sherbrooke for development projects

Beyond the preview

Go deeper on Simmunome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Simmunome.

Explore the full profile